ADC Therapeutics SA
$ 1.06
-3.64%
11 Jun - close price
- Market Cap 139,910,000 USD
- Current Price $ 1.06
- High / Low $ 1.14 / 1.06
- Stock P/E N/A
- Book Value -1.70
- EPS -0.97
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -7.06 %
- 52 Week High 4.98
- 52 Week Low 0.78
About
ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.
Analyst Target Price
$5.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-04 | 2026-03-10 | 2025-11-10 | 2025-08-12 | 2025-05-14 | 2025-03-27 | 2024-11-07 | 2024-08-06 | 2024-05-06 | 2024-03-13 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.21 | -0.04 | -0.3 | -0.5 | -0.36 | -0.29 | -0.42 | -0.38 | -0.56 | -1.03 | -0.58 | -0.58 |
| Estimated EPS | -0.2 | -0.2983 | -0.36 | -0.48 | -0.4143 | -0.41 | -0.39 | -0.46 | -0.56 | -0.5 | -0.63 | -0.57 |
| Surprise | -0.01 | 0.2583 | 0.06 | -0.02 | 0.0543 | 0.12 | -0.03 | 0.08 | 0 | -0.53 | 0.05 | -0.01 |
| Surprise Percentage | -5% | 86.5907% | 16.6667% | -4.1667% | 13.1064% | 29.2683% | -7.6923% | 17.3913% | 0% | -106% | 7.9365% | -1.7544% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.21 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADCT
2026-06-11 14:10:19
Pomerantz LLP is investigating potential claims against ADC Therapeutics SA (NYSE: ADCT) on behalf of investors. This investigation follows a significant drop in ADC's stock price after the company announced topline data from its Phase 3 LOTIS-5 trial, revealing a higher number of deaths in the ZYNLONTA® treatment arm compared to the immunotherapy arm. The law firm is seeking to determine if ADC and its officers engaged in securities fraud or other unlawful business practices.
2026-06-10 12:09:06
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (ADCT) securities. This investigation follows a significant drop in ADC's stock price after the announcement of topline data from its Phase 3 LOTIS-5 trial, which showed an extended progression-free survival but also a higher number of deaths for patients treated with ZYNLONTA®. Investors are encouraged to contact the firm to learn more and assist the investigation.
2026-06-08 23:40:03
ADC Therapeutics (ADCT) recently reported mixed Phase 3 LOTIS-5 data for ZYNLONTA, showing improved progression-free survival in lymphoma but also higher rates of serious adverse events, particularly in older patients. This mixed profile is now central to discussions with regulators and could impact ZYNLONTA's label and the company's future growth. The article explores how this data might affect ADC Therapeutics' investment narrative, emphasizing dilution risk due to ongoing losses and regulatory uncertainty, while also noting that analysts projected significant revenue and earnings growth by 2028 based on a $7.50 fair value.
2026-06-08 23:10:04
ADC Therapeutics SA (ADCT) has published a slide deck discussing the results of its Phase III LOTIS-5 trial and outlining the next steps for its treatment of Diffuse Large B-cell Lymphoma (DLBCL). The article highlights the company's detailed presentation on the trial's findings.
2026-06-06 12:09:06
ADC Therapeutics (ADCT) stock is falling after the company announced that its Phase 3 LOTIS-5 trial for ZYNLONTA showed elevated serious and Grade 5 adverse events, despite meeting its primary endpoint of progression-free survival in patients with relapsed or refractory diffuse large B-cell lymphoma. The company plans to discuss the benefit-risk profile with the FDA and prepare for an sBLA submission in Q4 2026. This news led to a significant drop in ADCT shares during premarket trading.
2026-06-05 15:40:24
ADC Therapeutics' drug Zynlonta has met its primary endpoint for progression-free survival in a Phase III trial for diffuse large B-cell lymphoma (DLBCL). Despite this positive efficacy result, ongoing safety concerns, particularly regarding respiratory issues and patient deaths, are expected to complicate its path to FDA approval for broader indications. The company has previously halted studies due to these safety issues.
